Patents by Inventor Raphael Darteil

Raphael Darteil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION
    Publication number: 20240100125
    Abstract: The present invention relates to a synergistic combination of an FXR agonist and interferon for the treatment of hepatitis B.
    Type: Application
    Filed: January 13, 2022
    Publication date: March 28, 2024
    Inventors: RAPHAËL DARTEIL, PIETRO SCALFARO, JACKY VONDERSCHER, ELISE ROY, DAVID DURANTEL
  • THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS
    Publication number: 20230321033
    Abstract: The present invention relates to a method for treating renal fibrosis.
    Type: Application
    Filed: August 5, 2021
    Publication date: October 12, 2023
    Inventors: RAPHAËL DARTEIL, STÉPHANIE LE CORRE, ERIC MELDRUM, FABIOLA TERZI, JACKY VONDERSCHER
  • METHOD FOR TREATING CHRONIC KIDNEY DISEASES
    Publication number: 20230165853
    Abstract: The present invention relates to a method for treating chronic kidney diseases.
    Type: Application
    Filed: January 13, 2022
    Publication date: June 1, 2023
    Inventors: FABIOLA TERZI, RAPHAËL DARTEIL, PIETRO SCALFARO, JACKY VONDERSCHER, HUGO GIRMA
  • USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS
    Publication number: 20230060715
    Abstract: The present invention relates to the use of a farnesoid X receptor (FXR) agonist for the treatment of hepatitis D infection.
    Type: Application
    Filed: January 14, 2021
    Publication date: March 2, 2023
    Inventors: RAPHAËL DARTEIL, JULIE LUCIFORA, DAVID DURANTEL, CHRISTOPHE RAMIERE, BENOÎT LACOMBE, VINCENT LOTTEAU, PATRICE ANDRE
  • METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20220411874
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 29, 2022
    Applicant: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • SYNERGISTIC EFFECT OF EYP001 AND IFN FOR THE TREATMENT OF HBV INFECTION
    Publication number: 20220313690
    Abstract: The present invention relates to a synergistic combination of EYP001 and interferon for the treatment of hepatitis B.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 6, 2022
    Inventors: JACKY VONDERSCHER, ELISE ROY, RAPHAËL DARTEIL, PIETRO SCALFARO
  • IMPROVED TREATMENT USING EYP001
    Publication number: 20220249469
    Abstract: The present invention relates to a method of treatment with an FXR agonist allowing to decrease pruritus and improve efficacy.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 11, 2022
    Inventors: JACKY VONDERSCHER, ELISE ROY, RAPHAËL DARTEIL, PIETRO SCALFARO
  • METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON
    Publication number: 20220241376
    Abstract: The present invention relates to a method for decreasing adverse-effects of interferon and to new compositions and methods of treatment.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 4, 2022
    Inventors: JACKY VONDERSCHER, ELISE ROY, RAPHAËL DARTEIL, PIETRO SCALFARO
  • Methods for diagnosing and evaluating non-alcoholic steatohepatitis
    Patent number: 11371098
    Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 28, 2022
    Assignee: Genfit
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 11103484
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 31, 2021
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10905680
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: GENFIT
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS
    Publication number: 20200384105
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 10, 2020
    Inventors: Raphael DARTEIL, Rémy Hanf, Dean Hum, Ingrid Dufour
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20200316031
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10722575
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 28, 2020
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20190352715
    Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
    Type: Application
    Filed: March 30, 2017
    Publication date: November 21, 2019
    Applicant: Genfit
    Inventors: Raphael Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS
    Publication number: 20190275146
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 12, 2019
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10350181
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 16, 2019
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20190083468
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20190000813
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130613
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille